Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > How to lower the barriers to nanotechnology transfer

Abstract:
A major challenge for nanobusiness is to find a unique selling proposition, out of a diverse range of possible applications. Potential investors need better understanding of nanotech-related business opportunities.

How to lower the barriers to nanotechnology transfer

Brussels, Belgium | Posted on March 9th, 2012

Researchers typically define nanotechnology research outputs as ‘platform' technologies with a diverse range of applications. Moreover, nanotechnology is often an enabling technology used to improve existing products rather than create entirely new products. The wide range of potential applications typically associated to nanotechnologies can bring forward remarkable business opportunities but it can also turn into risk if not properly understood and prioritized. Among researchers, there is still a widespread lack of market understanding and assessment of the real business benefits associated with each application.

On the other hand, investors' understanding of nanotechnology is at an early stage, compared to more established business sectors. Typically, investors are focused on the commercial potential of the end-product and little concerned about the underlying technology being "nano" or not. What they need is a clear assessment of market potential and control of the source and level of finance needed. They will be reluctant, if they don't understand very well the business opportunities that nanotechnology brings. Even more, some investors fear that the "nano promise" may be unjustified as it happened with the "dot com bubble". Investors need to be assured of nano's commercial potential and benefits.

A clear commercial focus is key to ensure investors' control of the source and level of finance needed: this is a key insight from the EC funded ProNano project analysis of barriers to the commercialization of nanotechnologies. ProNano has looked for new actions to reduce barriers and pro-actively develop routes to commercialisation from an early stage.

According to the ProNano advisors, the challenge for nano-businesses is to clearly set market priorities within the range of potential applications coming form nanotechological innovation: investors need market validation. Businesses should be able to identify their own ‘unique sales proposition'. The common denominator for problems concerning turning nanotechnology into a commercial venture is not the technology but the definition of a suitable business model able to attract investors. This problem is seriously underestimated. Through a clearly defined business model, which is coherently based on the strength of the technology itself as well as on the market value the technology may have, nanotechnological results may attract appropriate financing. As was the case with biomedical innovations, it will take time for researchers to break down the barriers and bring their nanotechnological innovations to the market. ProNano is helping the entrepreneur in developing a coherent finance raising strategy linked to market and customer prioritisation.

####

For more information, please click here

Contacts:
Elisabeth Schmid
Phone: + 39 02 700 25 71
Fax: + 39 02 700 25 40

Copyright © youris.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project